A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

NCT02512068 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
107
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda